



Appendix 11 (as supplied by the authors): Differences between insulin analogues and conventional insulins in terms of glycemic control (weighted mean difference in hemoglobin A_{1c}) in the management of type 2 diabetes mellitus in adults

A: Comparison of insulin lispro (or biphasic insulin lispro) versus regular human insulin (or biphasic human insulin)




CI=confidence interval; ILis=insulin lispro; HI=regular human insulin; SD=standard deviation; WMD=weighted mean difference

B: Comparison of insulin aspart (or biphasic insulin aspart) versus regular human insulin (or biphasic human insulin)




CI=confidence interval; IAsp=insulin aspart; HI=regular human insulin; SD=standard deviation; WMD=weighted mean difference

C: Comparison of insulin glargine versus insulin NPH (both in combination with oral antidiabetic therapy)



CI=confidence interval; IGlar=insulin glargine; NPH=insulin NPH (neutral protamine Hagedorn insulin); OAD= oral antidiabetic agents ; SD=standard deviation; WMD=weighted mean difference

D: Comparison of insulin detemir versus insulin NPH (both in combination with oral antidiabetic therapy)



CI=confidence interval; IDet=insulin detemir; NPH=insulin NPH (neutral protamine Hagedorn insulin); OAD= oral antidiabetic agents ; SD=standard deviation; WMD=weighted mean difference